17:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers; other

TECHNOLOGY: Bioinformatics; gene profiling; computational models Computational models based on tumor levels of lncRNAs could help predict resistance to cancer therapies. The method involves a machine learning algorithm that uses the expression levels of 2,614...
23:37 , Sep 17, 2018 |  BC Extra  |  Tools & Techniques

AI code could speed cancer diagnosis, treatment decisions

New York University School of Medicine researchers described in Nature Medicine a machine learning-based program that can distinguish lung cancer subtypes and at least six driving mutations using only histological slide images, in less time...
21:36 , Sep 17, 2018 |  BC Extra  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
17:36 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

Keeping CRISPR on target

Editas Medicine Inc. (NASDAQ:EDIT) has developed an in silico model of Staphylococcus aureus Cas9 (SaCas9) gene editing to help it select guide RNA sequences with minimal risk of off-target effects. Editas’ lead candidate EDIT-101 is built...
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models An algorithm based on cytometric data from multiple studies could help identify cell populations as diagnostic or prognostic markers of disease. The algorithm involves three steps. First, it processes raw...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
17:59 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Other

TECHNOLOGY: Computational models A computational model based on T cell function could help predict responses to checkpoint inhibitors in cancer patients. The model, dubbed Tumor Immune Dysfunction and Exclusion (TIDE) predictor, was generated in two...
22:08 , Aug 23, 2018 |  BC Innovations  |  Product R&D

Sweet switch

Novo Nordisk A/S is betting Ziylo Ltd.’s glucose-responsive compounds can unlock development of smart insulins that are a step up for diabetes therapy. Unlike the competitors, which mostly act when blood glucose is high, Ziylo’s...
22:18 , Aug 21, 2018 |  BC Extra  |  Preclinical News

Two algorithms could better predict response to checkpoint inhibitors

While checkpoint inhibitors have revolutionized immunotherapy, many patients don't respond to the inhibitors, and there are currently no accurate diagnostics to predict who will respond. Two papers in Nature Medicine put forth algorithms that use...